We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BIO, Two Drugmakers Side with Amgen in Biosimilar Case
BIO, Two Drugmakers Side with Amgen in Biosimilar Case
An industry group and two drugmakers have filed briefs in the Supreme Court backing Amgen’s request that a federal circuit ruling be partially affirmed to mandate that biosimilar makers share information and wait six months after an FDA approval to launch a therapy.